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Recent advancements in point-of-care (PoC) technologies show great transformative
promises for personalized preventative and predictive medicine. However, fields like ther-
apeutic drug monitoring (TDM), that first allowed for personalized treatment of patients’
disease, still lag behind in the widespread application of PoC devices for monitoring of
patients. Surprisingly, very few applications in commonly monitored drugs, such as anti-
epileptics, are paving the way for a PoC approach to patient therapy monitoring compared
to other fields like intensive care cardiac markers monitoring, glycemic controls in diabetes,
or bench-top hematological parameters analysis at the local drug store. Such delay in the
development of portable fast clinically effective drug monitoring devices is in our opinion
due more to an inertial drag on the pervasiveness of these new devices into the clinical
field than a lack of technical capability. At the same time, some very promising technologies
failed in the clinical practice for inadequate understanding of the outcome parameters nec-
essary for a relevant technological breakthrough that has superior clinical performance. We
hope, by over-viewing bothTDM practice and its yet unmet needs and latest advancement
in micro- and nanotechnology applications to PoC clinical devices, to help bridging the two
communities, the one exploiting analytical technologies and the one mastering the most
advanced techniques, into translating existing and forthcoming technologies in effective
devices.
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INTRODUCTION
Most of the technological efforts in diagnostic research aims at
designing better tools for the diagnosis, treatment, and prog-
nosis of patients’ disease with different strategies, so to provide
faster, more sensitive, cheaper, portable, reliable, and less invasive
devices (Tüdo˝s et al., 2001; Walt, 2005; Soper et al., 2006; Vyawa-
hare et al., 2010). As the technologies become available, medicine
tries to accommodate inter-individual and intra-individual vari-
ability into the picture (Hood et al., 2004; Hamburg and Collins,
2010), in an effort to personalize treatment and improve the clin-
ical outcome and the quality of life for the patients (Ginsburg and
McCarthy, 2001; Meyer and Ginsburg, 2002; La Thangue and Kerr,
2011). Such efforts may be grouped as biomarker discovery (Rifai
et al., 2006; Amur et al., 2008) and monitoring (Phillips et al.,
2006; Hamburg and Collins, 2010). This comprehensive approach
to identify and measure molecular entities with high-sensitivity
(Rusling et al., 2010) provide good, though often surrogate, estima-
tors with good clinical performance in diagnosing or monitoring
patient’s disease and treatment (Ginsburg and McCarthy, 2001;
Rifai et al., 2006; Kelloff and Sigman, 2012; Pennello, 2013).
The enormous advancements in genomic and proteomic
microarrays studies in the latest 15 years have been a driving force
toward the development of fast, automatized, high-throughput,
multiplexing diagnostic techniques able to reliably process an
enormous amount of samples at a time. Usually, the skills required
not only for the sophisticated analysis but also especially for the
analysis of such large amount of data sets have confined these
analyses mainly to large facilities and dedicated centers. Build-
ing on the intrinsic high specificity and selectivity of nucleic
acid recognition, genetic analysis is the field that experienced
the most tremendous innovations, not only on high-throughput
ultrasensitive analytical and sequencing techniques but also on
miniaturized point-of-care (PoC) devices [see, for example, the
very recent review by Kelley et al. (2014)]. Highly sensitive tech-
nologies pushed micro- and nanotechnology application toward
single cell analysis (Wang and Bodovitz, 2010). In addition, the
importance of detecting genetic signatures to correctly diagnose
infectious disease, for example, stimulated further extension of
miniaturization from the micro- to the nanoscale of DNA analysis
for rapid turn-around time (TAT) serotyping of infective agent
that with standard techniques (such as culturing the specimen)
would require days or weeks.
Biomarker detection research is pursuing clinically significant
performance of diagnostic technologies through two main paths.
On one side, there is the yet unmet need for ultrasensitive detec-
tion of few biomolecules per specimen for early disease diagnosis
and surveillance. On the other hand, state-of-the art analytical
technologies may have already reached appropriate sensitivity,
but have too slow TAT to warrant sufficient clinical outcomes
to benefit the patient. Therefore, diagnostic devices with sample-
to-answer TAT compatible with a visit at the physician’s office
are another promising transformative area of research. Compared
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to available analytical methodologies, which provide sensitivity
with costly, dedicated and sophisticated machinery in centralized
labs, new devices are designed to be used at the proximity of the
patient, whether this means at the patient’s home, the doctor’s
office, the emergency room or in small decentralized, capillary
spread laboratories (as drug-stores, for example). Ideally, such new
devices would also provide less invasive sampling method and no
requirement for sample pretreatment and specialized skills, like
the analysis of a blood drop from a fingerprick or saliva from
an oral swab. In such a scenario, the target analyte concentration
in the biological fluids may fall in a non-analytically challenging
range. However, sensitivity issues may still arise as a consequence
of the miniaturization and handling of small amount of patient’s
specimen containing few analyte molecules.
Few pathological biomarkers are already in the clinical practice
(Hartwell et al., 2006), for example, the much discussed PSA, the
prostate-specific antigen (Hernández and Thompson, 2004). Clin-
icians, however, routinely monitor the pharmacodynamic effects
of therapies through easily accessible physiological parameters,
like blood glucose, glycated hemoglobin (HbA1c), blood pressure,
blood cell count, clotting tests, chemico-physical variables like
PO2, PCO2, and electrolytes, and well established panels of meta-
bolic, lipid, liver, renal, and cardiac biochemical indices (Dasgupta
and Wahed, 2014).
For many of the easily accessible physiological parameters men-
tioned earlier, PoC devices are already available both for the physi-
cian’s office and the patients (Tüdo˝s et al., 2001; Lippi et al., 2010;
Chan et al., 2013) and encompasses different kind of technology
(Luppa et al., 2011). Detection of other potentially useful mark-
ers falls in analytically challenging concentration ranges, or relies
upon detection and read-out technologies that are technically chal-
lenging to be re-designed for miniaturization (Cheng et al., 2006;
Craighead, 2006; Rusling et al., 2010; Cima, 2011).
In particular, chronic diseases requiring continuous monitor-
ing of therapy (like anti-diabetes and anti-coagulants) have been
the first ones for which PoC devices entered the home of the
patients (St John and Price, 2014), allowing for timely and con-
stant monitoring of therapy outcome, and improving quality of
care over centralized-lab testing (Tüdo˝s et al., 2001; Luppa et al.,
2011). A textbook example is the blood glucose meter (Newman
and Turner, 2005; Wang, 2008). This extremely portable device
seamlessly links the patient to the result of his/her own daily
monitoring of therapy. The patient can easily monitor glucose
concentration in blood through a fingerprick, and adjust ther-
apy or refer to the physician. In addition, a variety of glucose
meter of few centimeters in size is available to the end user for
few tens of dollars (plus test strips costs) that devolve the dis-
play of results to smartphones (Lillehoj et al., 2013). Finally, the
extensive knowledge of the pharmacokinetics (PK) and the phar-
macodynamics (PD) of insulin drove the design of automatized
closed loop system integrating blood measurements, evaluation,
and dosage adjustment and administration in a small, wearable
(and soon implantable) lab-on-a-chip (LoC) devices (Hirsch et al.,
2008; Cima, 2011; Bandodkar and Wang, 2014).
However, blood glucose concentrations in diabetic patients
are in the millimolar range, easily achievable technically com-
pared to the 108 times smaller concentration of most biomarkers
(Craighead, 2006; Chin et al., 2012; Chan et al., 2013). The read-
out is usually an electrochemical determination (most commonly
amperometry) of enzyme activity induced by the presence of glu-
cose (Wang, 2008), that can be easily implemented with cheap
consumer electronic components. In addition, the frequency and
amount of measurements performed daily likely exceed that of any
other parameter to be monitored, making the market very appeal-
ing (Newman and Turner, 2005). Similarly, PoC clotting tests are
also widely used as companion monitoring during anticoagulant
therapy (Chin et al., 2012; St John and Price, 2014).
Microfabrication and especially the recent advancement in
microfluidics have been the leading protagonists of the devel-
opment of miniaturized laboratory testing (lab-on-chip) devices,
with excellent translation into practice with PoC devices (Tüdo˝s
et al., 2001; Vyawahare et al., 2010; Luppa et al., 2011). Recent pub-
lications offer detailed reviews of the most recent PoC and LoC
devices under development or already available on the market
(Toner and Irimia, 2005; Soper et al., 2006; Yager et al., 2008; Mark
et al., 2010; Chin et al., 2012; Lisowski and Zarzycki, 2013; Gauglitz,
2014; St John and Price, 2014). As perspicuously detailed by Chin
et al. (2012), despite the remarkable advances in the development
of single LoC components, few microfluidic technologies have made
the leap to fully functional integrated devices with real clinical value.
Indeed, a plethora of different high-sensitivity techniques emerged
in the literature. However, despite the high-performance of the
individual parts, the final fully integrated device may not be feasi-
ble at all due to poor compatibility of its single components, poor
understanding of the end-use settings, and of the critical step in
the clinical pipeline. Eventually, they also may demonstrate limited
improvement of quality of care compared to the cost reduction or
easiness of use.
Trends in the development of PoC devices are different depend-
ing on the end-use settings, like high- or low-income countries
(Martinez et al., 2010), local clinical laboratory, physician’s office
or patient’s home, mobile use, emergency settings (Luppa et al.,
2011). The ideal PoC device, however, has to provide rapid TAT
sample to answer with no human intervention besides adding the
sample and collecting the data. Conventional hematological mark-
ers (like the ones mentioned earlier) that are routinely monitored
and quantified in clinical laboratory can be evaluated through
small bench-top instruments, usually equipped with a series of dis-
posable cartridges for each panel of parameters, which permits the
creation of easily accessible diagnostics sites (Pollock et al., 2012;
St John and Price, 2014). Automatization and miniaturization,
in particular of the fluidic component, drove the development
of smaller machinery able to analyze few tens of microliters of
patient’s blood (with reduced reagent consumption) (Tarn and
Pamme, 2011). These results paved the way to powerful high-
throughput, multiplexed, fast platforms, which are very appealing
for large facilities and wide genomics/proteomics studies. Quan-
titative PoC system based on microfluidics and implementing
separation and sample pretreatment are gaining increased space
in the market (Luppa et al., 2011; Chin et al., 2012). Indeed, addi-
tional research goes in the direction of systems able to incorporate
or to waive specimen pretreatment, in particular blood separation
(Toner and Irimia, 2005; Songjaroen et al., 2012), viscous sam-
ple preparation (Ge et al., 2014), and electrophoretic separation
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(Govindarajan et al., 2011). These principles are implemented in
handheld instruments for the detection, for example, of cardiac
failure markers that ensure <30 min of TAT directly at the emer-
gency room and improve triage decision making (Chen et al.,
2014a), with great clinical impact that largely exceed the added
costs (Chin et al., 2012; St John and Price, 2013, 2014).
THERAPEUTIC DRUG MONITORING: A LITTLE EXPLORED
FIELD FOR PoC?
Parameters like coagulation indices or glycemia are examples of
easily accessible surrogate response (pharmacodynamic) biomark-
ers that monitor the therapeutic effect (Gross, 2001; Touw et al.,
2005). For many other therapies, the pharmacodynamic effect is
not readily measurable, and large inter-individual variation and
narrow therapeutic index make it very difficult to adjust dosage
without high risk of toxicity for the patients (Gross, 2001; Buclin
et al., 2012). Variability arises in the different absorption and dis-
tribution (pharmacokinetic) rates in different patients, that is, the
same dosage may translate into different drug concentrations and
different pharmacodynamic response to the same drug concen-
tration in different patients (Gross, 2001; Touw et al., 2005; Neef
et al., 2008; Buclin et al., 2012). When the population variability
is larger than the therapeutic range (that is the difference between
the minimum efficacy dose and the lowest dose at which adverse
effects arise), monitoring of therapy is crucial.
A long known companion of personalized medicine in these
situations is therapeutic drug monitoring (TDM) (Lesko and
Schmidt, 2012). The International Association for Therapeutic Drug
Monitoring and Clinical Toxicology defines TDM (Watson et al.,
1997) as “the measurement made in the laboratory of a parame-
ter that, with appropriate interpretation, will directly influence
prescribing procedure. Commonly the measurement is in a bio-
logical matrix of a prescribed xenobiotic, but it may also be of
an endogenous compound prescribed as replacement therapy in
an individual who is physiologically or pathologically deficient in
that compound.”
Consensus is reached on the rational prescription of TDM,
which is – despite recent advancements – a demanding proce-
dure with non-negligible costs for the healthcare systems, both in
high- (Schumacher and Barr, 2001; Ghiculescu, 2008; Kang and
Lee, 2009; Buclin et al., 2012) and low- (Taur et al., 2013; Nwo-
bodo,2014) income countries. Guidelines recommend TDM when
the following circumstances occur (Gross, 2001; Schumacher and
Barr, 2001; Touw et al., 2005; Buclin et al., 2012): (1) when there
is a stronger (and ascertainable) relationship between the drug
concentration and its therapeutic effect or toxicity, rather than
between the administered dose and the effect. (2) If the thera-
peutic window is small. (3) If no simple accessible parameter is
available to evaluate the clinical efficacy. (4) When there is large
inter-individual variability in the pharmacokinetic (and some-
times in the pharmacodynamic) parameters. (5) When interac-
tion with co-medications, physiological and pathological changes
(intra-individual variations), or compliance issues arise.
Drug monitoring of therapy is helpful in intensive care situ-
ations (i.e., aminoglycosides antibiotic, vancomycin, caffeine in
neonatal apnea), but is mostly known for chronic therapy such
as immunosuppressant, anti-arrhythmic like digoxin, and many
anti-epileptic drugs (AED). As their therapeutic index is known
to be narrow, administration of these drugs is often accompa-
nied with TDM. The list of most commonly monitored drugs
(Gross, 2001; Schumacher and Barr, 2001; Dasgupta and Wahed,
2014) that meet the aforementioned criteria include – but is
not limited to – antiretrovirals (Acosta et al., 2002), carba-
mazepine, valproic acid, phenobarbital phenytoin and lithium
among anticonvulsants (Eadie, 2002), aminoglycosides and van-
comycin among antibiotics, cardiac drugs like digoxin (Valdes
et al., 1998), immunosuppressant as cyclosporine, tacrolimus,
mycophenolate mofetil (Johnston and Holt, 2001); anti-cancer
drug as methotrexate, bronchodilators as theophylline and caf-
feine, tricyclic antidepressant among psychiatric drugs (Hiemke
et al., 2011).
Drug monitoring helps to identify the onset response at the
beginning of therapy, and to adjust the dose in critical patient
(with renal, hepatic, or cardiac impairment, etc.). Then, it can be
performed at wider time interval to assess efficacy of the therapy,
to build a reference range for the patient under evaluation (Pat-
salos et al., 2008). Moreover, intra-individual variation may occur
in the life of a patient due to the appearance of other conditions
over time (additional therapy, hepatic/renal/cardiac dysfunction,
pregnancy) that alter the metabolism of the drug and require
dosage adjustment (Patsalos and Perucca, 2003; Tomson, 2005;
Adab, 2006). TDM is an exceptional tool to better understand why
patients do not respond satisfactorily to a particular dose, and to
assess and monitor compliance and ultimately to study the vari-
ation in PK that occurs in different individuals and the factors
involved (Muller and Milton, 2012).
Anti-epileptic drugs are a very representative case of TDM
application to clinical practice (Neels et al., 2004; Patsalos et al.,
2008; Krasowski and McMillin, 2014). These drugs treat and pre-
vent the clinical manifestations, like seizures, only if an effective
drug concentration is reached, and present serious side effects
when reaching toxic concentration. Most of these drugs have nar-
row therapeutic index and large inter-individual variability (Eadie,
2002; Johannessen et al., 2003; Patsalos et al., 2008). Histori-
cally, the old generation anti epileptic drug phenytoin was one
of the first drug for which a TDM test was developed (1960)
(Eadie, 2002; Patsalos and Berry, 2013). Phenytoin presents both
a non-linear PK (that is, there is a non-linear relation between the
administered dose and the blood drug concentration) and high-
inter-individual variability. Other old generation anticonvulsants
like carbamazepine, valproic acid, ethosuximide, and phenobar-
bital are still used and monitored (Jannuzzi et al., 2000; Eadie,
2002; Patsalos et al., 2008; Krasowski and McMillin, 2014). Sec-
ond generation AEDs were marketed as safer because of a wider
therapeutic index, though practice revealed that achieving proper
dosage is challenging and TDM could be useful (Perucca, 2000;
Johannessen et al., 2003; Striano et al., 2008; Krasowski, 2010;
de Leon et al., 2013). Being epilepsy a chronic disease that affect
almost 3% of the population worldwide, for which TDM was
firstly introduced almost half a century ago, one would expect a
rather diffused availability of PoC devices for home-based therapy
management.
Many recent analyses tried to assess the cost–benefit for TDM of
different classes of drugs, and only a few were able to clearly assess
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the superior clinical performance – in terms of cost-effectiveness –
of routine TDM (Eadie, 2002; Touw et al., 2005; Tomson et al.,
2007; Salih et al., 2013). AEDs TDM is usually perceived as cost-
effective, because of the high risks associated with improper dosage
and the successes achieved in managing therapy with the proper
interpretation of TDM analysis (Glauser and Pippenger, 2000;
Buclin et al., 2012). In addition, for AEDs and many other drugs,
TDM studies would provide invaluable information on the PK of
drugs in subpopulation not well represented in the pharmacoki-
netic studies during trials, such as gender (Morrell, 1996; Tomson,
2005), pregnancy and newborns (Adab, 2006), children (Momper
and Wagner, 2013), and elderly people (Steinman et al., 2011).
While the contribution of TDM to the effective management of
therapy is substantiated by practice, properly designed studies are
missing, or evaluate too different clinical outcome variables that
prevent proper comparison (Touw et al., 2005; Tomson et al., 2007;
Salih et al., 2013). As health-care systems aim at providing services
at reduced cost whenever possible, rationalization of costly TDM
analysis prescription is everywhere highly recommended (Touw
et al., 2005; Ghiculescu, 2008). Unfortunately, the lack of con-
sensus on a clear-cut quantitative analysis in favor of distributed,
decentralized TDM procedures is slowing down the investment
and applications of PoC system in the field.
TRADITIONAL TDM PIPELINE
There is heterogeneity in how TDM is accomplished in differ-
ent centers (Gross, 2001; Schumacher and Barr, 2001; Neef et al.,
2008; Kang and Lee, 2009). Besides different analytical method-
ologies, and different specimen analyzed, there are differences in
the kind of information that is provided to the treating physician.
For the value to be informative, drug measurements need to be
accompanied by proper detailed information about dosing sched-
ule, last dose administered timing, and sample timing (Aronson
and Hardman, 1992). Anyhow rarely, TDM service may provide
the drug concentration value per se, but more often it is accom-
panied at least by a reference range (validated for the sample and
technique employed) and with suggestion for clinical interpreta-
tion to be translated in therapeutic management. This reference
range is – as the name suggests – just a reference interval, statis-
tically defined, that encompasses the spread of the concentrations
in a population of patients addressed during clinical studies. It
may change for different therapeutic uses of the same drug, and
exact values of the boundary limits may change depending on the
analytical technique involved. The role of clinical pharmacolo-
gists is therefore gaining increasing interest as novel theoretical
approaches to PK and PD studies allow for highly predictive
model to estimate proper dosage adjustment from the analysis
of the patients’ drug concentrations. Other critical details are co-
medications and demographics, like age, gender, and eventually
ethnicity [as pharmacogenomics studies distinguished specific,
in distinct subpopulations, in metabolic enzymes responsible for
altered metabolism and toxicity risks of certain drugs (Gurwitz
et al., 2003; Anderson, 2008)].
Unfortunately, as Phase II and Phase III of drug development
clinical trials require dose tolerance and dose response explo-
ration only, PK investigations are often a secondary objective
(Touw et al., 2005; Neef et al., 2008). Most of the drugs reaches
Phase IV (the post-marketing phase) with very little information
on the PK and PD behavior of the drug, and rarely with esti-
mation on the appropriateness of accompanying TDM, which is
left to the responsibility of practitioners (Gross, 2001; Neef et al.,
2008; Muller and Milton, 2012; Momper and Wagner, 2013). In
consequence, decentralization of the TDM analysis have been per-
ceived as very critical and potentially detrimental to the control
of patient’s therapy, as many general practitioner do not have the
expertise to provide interpretation of the analytical results. More-
over, for most drugs, the need for TDM in proper management of
therapy was discovered only in clinical practice.
However, in principle, having the PK and PD data available
for the monitored drug, current computational techniques would
allow full integration of these calculations in portable devices to
provide a proper reference range delivered with the analytical
answer, and would allow for fast results during the visit at the
physician office (for example), and for direct communication of
the results to the centralized lab for continuous therapy surveil-
lance. These pieces of information help, together with the clinical
and dosage history of the patient and the knowledge of the PK
and PD profiles of the drug, the clinical interpretation of the mea-
sured value and inform proper changes to therapy and therefore
improving the patient’s benefit and minimizing hospitalization
and hospital personnel costs.
Many groups call for mandatory TDM in drug development
clinical trials (Neef et al., 2008; Muller and Milton, 2012), which
require the concurrent development of an in vitro diagnostic test
for the drug (Pirmohamed, 2010; Shimazawa and Ikeda, 2015).
Concentration-Controlled Randomized Clinical Trials (CCRCT)
design was suggested more than 20 years ago (Sanathanan and
Peck, 1991), because of the improved sample size efficiency, but it
is still very little implemented (Lledó-García et al., 2009; Momper
and Wagner, 2013). Advancement in PK–PD modeling allow for
prediction of the average response profile to a given dosage and
evaluation of a therapeutic margin; for identification of suscep-
tibility factors that alter the therapeutic/toxic response, and for
quantification of variability response, that can account also for
random population variability (Lledó-García et al., 2009; Muller
and Milton, 2012; Momper and Wagner, 2013). Establishment of
proper PK–PD characterization during drug development gen-
erates detailed knowledge of PK–PD parameters that constitute
solid reference for translation of dosage adjustment (or for sub-
sequent clinical trials) in the targeted patient’s population and,
more importantly, in subpopulations overly under-represented in
drug development (Walson, 1998), like pregnancy (Ke et al., 2014),
infants (Koren, 1997; Momper and Wagner, 2013), and elderlies
(Battino et al., 1995; Perucca, 2005, 2006; Steinman et al., 2011;
Etwel et al., 2014).
Besides the burden of additional blood sampling to the enrolled
patients, the main hurdle to TDM inclusion in drug development
and investigational trials (and practice) is cost (Neef et al., 2008;
Shimazawa and Ikeda, 2015). Indeed, incorporation of TDM in
drug development requires additional investments from the indus-
try in the development of a robust, validated bioanalytical assay.
In addition, TDM is somehow also perceived by companies as a
potential barrier for the subsequent effortless adoption of the drug
in the clinical practice (Neef et al., 2008; Shimazawa and Ikeda,
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2015). Both the increase in costs for drug developments along
with a lack of awareness of the regulatory authorities and hence
the obligation for companying TDM during drug development
and approval led to the fact that little investment and research
effort is made in the field, even so the new developments in terms
of nanotechnology for sensor techniques are promising.
The main points where improvements need to be made and
can be gained with nanotechnologies are to increase the sensitiv-
ity in order to work with smaller sample volumes allowing for
a repeated sampling or even more non-invasive sampling such as
tears or sweat. Smaller volumes also mean that the time of reaction
with the sensor system decreases and hence the time-to-result.
The most commonly employed technologies for TDM so far
have been extensively revised for the different classes of drugs
[see, for example, Dasgupta and Wahed (2014)]. Usually, drug
concentration is monitored from a plasma sample, though whole
blood could also be analyzed (Aronson and Hardman, 1992;
Reynolds and Aronson, 1993). Sample treatments extract the total
drug available in plasma that is the sum of the protein-bound
and free drug in circulation. Depending on the assay chosen,
the analytical protocol has to be validated at each step from the
pre-analytical phases to result communication and storage. The
pre-analytical phase includes patient preparation, sample collec-
tion, sample treatment, and is often unique to the drug to be
analyzed. For example, lithium therapy monitoring cannot be
performed on sample collected in standard lithium heparin blood
tubes, and colorimetric tests may suffer the interference of a poorly
drawn blood sample (from hemoglobin interference) (Aronson
and Hardman, 1992; Reynolds and Aronson, 1993; Dasgupta and
Wahed, 2014).
Analytical separation techniques are widely established
methodologies for TDM. High-performance liquid chromatog-
raphy (HPLC) (Taylor, 2005), capillary electrophoresis (EC)
(Kataoka et al., 1998; Pucci and Raggi, 2005), liquid or gas chro-
matography (LC or GC) coupled with UV spectroscopy (Serral-
heiro et al., 2013), or mass spectrometry (MS or eventually tandem
MS, MS/MS) (Maurer and Peters, 2005) have been extensively
applied to different varieties of pharmaceutical and abuse drugs
with excellent performances (Brandhorst et al., 2012), with opti-
mized protocols for the simultaneous separation and analysis of
multiple drugs at a time, such as in the case of co-medication
therapy, or simply, when analysis of a drug and its metabolite(s) is
necessary.
Appropriate sample pretreatment is required. It involves sol-
vent or solid-phase extraction (Bugamelli et al., 2002; Vermeij
and Edelbroek, 2007; Tonic-Ribarska et al., 2012) of the ana-
lyte from the biological matrix, though some publications report
direct injection of plasma into an online separation/analysis sys-
tem (HPLC-MS) (Martinavarro-Dominguez et al., 2002). These
techniques rely upon sophisticated and expensive equipment that
has to be operated by technically skilled personnel and are usually
more common in large clinical research laboratory.
In large laboratory hospitals, immunoassays with different
read-out technologies, ranging from nephelometry, chemilumi-
nescence, to colorimetry and fluorescence (see Figure 1 for a
survey of these techniques), are available for a panel of drugs
in multi-well plate assays with ready-made proprietary reagents
compatible with automatized commercial system already in use for
other analyses. These commercial systems often include automa-
tized sample pretreatment. Protocols may differ among centers,
and each center performs a proper analytical validation of the
methodological protocol and the entire process, as guidelines
require ensuring accurate and robust analyses (Shipkova et al.,
2014). Some immunoassays fall short of simultaneous determi-
nation of a drug and its active metabolite (Mikel et al., 2012), or
in the presence of co-medications that may cross react with the
antibody used for the assay. Different commercial assays present
different (or none) cross-reactivity patterns, for many of which
the literature offers details (Kang et al., 2011; Brandhorst et al.,
2012; Shipkova et al., 2014), though the expertise of the clinical
laboratory is pivotal in the recognition of interfering factors in
abnormal analyses.
Compared to sophisticated techniques, large-scale technique
like GC-MS, HPLC-UV, or HPLC-MS/MS (and variations) requir-
ing sample volumes of some milliliters, immunoassays are easily
and readily miniaturized by employing nanostructured surface
sensors or micro and nanoparticles (NP), and microfluidic ver-
sions of these analytical devices are already available for research
purposes. However, as most of the immunoassays rely upon
plasma samples, pre-treatment is an issue, and the lack of inte-
grated sample treatment in a miniaturized device is going to
impede its usefulness as a PoC technology. Typically, therapeutic
drug concentration are measured in plasma, but also whole blood
or saliva are tested (Chiappin et al., 2007); other biological matri-
ces such as hairs, tears, meconium, stool, urine, cerebrospinal fluid
(Caplan and Jenkins, 2008; Neef et al., 2008; Buclin et al., 2012),
and sweat are rarely used in clinical TDM routine, but are often
explored in drug abuse and patient’s compliance investigations
(George and Braithwaite, 2002).
There are special cases, like neonates, children, and adolescents
(MacLeod, 2010), which require more frequent monitoring from
the onset to the stabilization of therapy. Indeed, pharmacokinetic
parameters present wide inter-individual variability at the neona-
tal and infancy stage, and undergo rapid maturational changes
that make safe and effective dosing a burdensome challenge
(Perucca, 2005; MacLeod, 2010). Later in development, patient’s
growth requires therapy adjustments that must be individualized,
as growth rates are different among children population. Cheaper,
sensitive, miniaturized devices able to shift the monitoring at the
physician office or at the patient’s home would allow for metic-
ulous and less stressful and invasive time sampling, e.g., at the
manifestation of toxic symptoms, or saving patient’s and skilled
personnel time. Such an implementation would improve the clin-
ical performance of the monitoring by improving not only cost
containment but also, most importantly, patient’s quality of life.
TOWARD PoC MONITORING OF AEDs
To the best of our knowledge, very little of PoC technologies have
been translated to therapeutic AED monitoring. Development of
novel, cheap, and eventually PoC devices seems to be trapped
into a paradox. Despite the transformative potential on therapy
management, investors seem to be not significantly attracted by
the development of novel devices, because of the lack of clear
meta-analysis and trials on the cost-effectiveness and cost-utility
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FIGURE 1 | A summary of the most commonly employed homogeneous
competitive assays inTDM (Touw et al., 2005; Dasgupta andWahed,
2014). In fluorescence polarization immunoassay (FPIA) after incubation, the
fluorescence polarization signal is measured without separation of bound
from free labels. Free labeled analyte analog molecules are added to the
sample, and it has a different Brownian motion than when the label is bound
to a large antibody (Ab). When the analyte is present, there is competition for
the binding to the Ab. If the labeled analyte is bound to the Ab molecule then
the signal is generated, while when the labeled antigen is free in solution no
signal is produced. Therefore, signal intensity is inversely proportional to the
analyte concentration. Enzyme multiplied immunoassay technique (EMIT).
Free analyte analog molecules labeled with an enzyme, e.g.,
glucose-6-phosphate dehydrogenase enzyme, are added to the test solutions
to compete to the analyte to be tested. The active enzyme reduces NAD (no
signal) to NADH (absorbs at 340), so that absorbance is monitored at 340 nm.
When labeled analyte binds to the Ab, the enzyme becomes inactive, and so
the signal is generated by the free label, and signal intensity is directly
proportional to the analyte concentration. Luminescent oxygen channeling
immunoassay (LOCI). The reaction mixture is irradiated to generate singlet
oxygen species in microbeads coupled to the analyte. When bound to the
respective Ab molecule, also coupled to another kind of bead, the analyte
reacts with singlet oxygen and chemiluminescence signals are generated
proportionally to the concentration of the analyte–Ab complex. Kinetic
interaction of microparticle in solution (KIMS) and the conceptually similar
particle enhanced turbidimetric inhibition immunoassay (PETINIA). In the
absence of the analyte, free antibodies bind to drug microparticles conjugates
to form aggregates that absorb in the visible range. Absorbance (or
turbidimetry) is monitored and in presence of the analyte the Ab binds to the
free analyte preventing microparticle aggregation; a reduction in absorbance
is observed (signal is inversely proportional to analyte concentration). Cloned
enzyme donor immunoassay (CEDIA). An enzyme (like beta-galactosidase) is
genetically engineered into two inactive fragments: a small one called
enzyme donor (ED) conjugated with the drug analog, and a larger fragment
enzyme acceptor (EA): when the two fragments associate, the full enzyme
converts a substrate into a cleaved colored product. If drug analyte molecules
are present, they will compete with the ED-labeled drug in solution for the
limited Ab sites, so that free ED-labeled drug analog will bind to EA
generating a colorimetric signal directly proportional to the amount of analyte.
analysis of TDM practice (Billings, 2006). TDM trials do not
receive adequate funding as it is not yet mandatory for industries
to include TDM in drug development and government may prefer
not to fund with public grants research on industry’s marketable
products. In addition, despite the fact that the new Horizon 2020
is focused on translation of research to industrial products, TDM
was not identified as a potentially under-financed field. At the same
time, the lack of a simple, easy-to-use, and cheap device that repro-
ducibly measures drugs in patient-friendly matrices slows down
the collection of useful PK and PD data able to improve TDM prac-
tice (Neef et al., 2008). A promising recent study is employing the
bio-nanochip device (Jokerst and McDevitt, 2010; Du et al., 2011)
for saliva monitoring of phenobarbital and phenytoin through
a micro-bead assisted immunoassay, ready to be employed into
a clinical trials for TDM in epileptic children. The chip com-
prises a programmable chemical processors and assay AEDs with
a bead-based immunoassay. It is the first pilot study of the adap-
tation of an existing fully integrated (miniaturized) PoC device to
AEDs TDM (Fitzgerald, 2014).
However, some centers have simply and elegantly circumvented
the need for hospital visit in TDM, especially in monitoring of
pediatric patients, through collection of dried blood spot (DBS)
(Edelbroek et al., 2009; Wilhelm et al., 2014). DBS was introduced
by Guthrie and Susi (1963) for low invasive neonatal screening
of metabolic disorders. Paper substrates and sampling guidelines
are well characterized in this respect, as rigid quality standard
requirements are present, thus translation into TDM practice was
facilitated, though no established specific guidelines are presents
for TDM. The patient, the caregiver, or the personnel of small lab-
oratories collect a drop of peripheral blood on a marked paper card
that can be mailed back to the reference hospital, where the spot
is treated so to extract the drug to be analyzed (Edelbroek et al.,
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2009; Demirev, 2013; Shah et al., 2013; Ostler et al., 2014). The
possibilities of saliva as a vehicle to carry out non-invasive mon-
itoring (Aps and Martens, 2005; Chiappin et al., 2007; Schipper
et al., 2007; Malamud, 2011) has been long explored and identi-
fied some AEDs for which the fluid is a suitable medium for their
measurement (Liu and Delgado, 1999; Jones et al., 2005; Patsalos
and Berry, 2013), particularly in children or if monitoring needs to
be done frequently (Liu and Delgado, 1999; Tennison et al., 2004;
Patsalos and Berry, 2013).
Both strategies (saliva and DBS) open the prospect of strategi-
cally timed self-collection of the fluid by the patient in his or her
home, providing for direct assessment of drug concentration as
seizures, intermittent symptoms or side effects occur. More over,
they offer patient-friendly access to additional sampling for PK
and PD studies during trials (Chee et al., 1993; Gorodischer et al.,
1997; Kong et al., 2014). Although mailing the samples back to
the hospital does not shorten the time necessary to get the TDM
evaluation (Jones et al., 2005), the procedure allows for the moni-
toring of the patient at the exact time of the discomfort symptoms.
This provides useful information to proper therapy individualiza-
tions ensuring better management of adverse effects, which are the
major cause of patient’s reduced compliance. Posting of samples
to the laboratory (Tennison et al., 2004; Jones et al., 2005; Wilhelm
et al., 2014) for subsequent analysis translates into saved costs both
as personnel time and as improved quality of life for the patient.
If the outcome of therapy management is measured solely as, for
example, the patient’s seizure-free interval, probably the differ-
ences between centralized and PoC testing performance are not
going to be sufficient to justify the added cost for the health-care
system of providing every patient or every general practitioner
a PoC device. However, when clinical performance is evaluated
including in the outcomes, the increased quality of life for the
patient, a tailored and comfortable monitoring procedure, and
most importantly the reduced loss in worked (or school) hours,
the balance is expected to be in favor of the PoC.
Information required for proper interpretation of TDM mea-
surements for DBS (and other specimens) samples are not different
for the ones required for serum sampling. As for traditional serum
TDM, the sample (and its results) needs to be accompanied and
evaluated with meticulous dosage history, sampling time, and clin-
ical evaluation. Timing of the sampling may be readjusted for saliva
sampling according to the drug PK (Jones et al., 2005; Schipper
et al., 2007). On one hand, home sampling and sample shipment
provide for lower cost and higher portability (in terms of easier
management for the patient, who does not have to travel to the
larger centers for proper analysis), and less skill for sampling. Yet,
the analysis per se still requires sophisticated techniques, and is
performed in dedicated centers. Generally, the pre-analytical steps
for DBS have to be carefully tested for the each specific drug.
For example, the hematocrit value is known to affect the viscosity
of the blood drop and its deposition on paper (Demirev, 2013;
Kong et al., 2014). In the lab, the chemist may choose to evaluate
the hematocrit directly, or indirectly via potassium measurements,
and proceed to viscosity adjustment before drop deposition. For
home sample collection, however, a different protocol has to be
established for the DBS sample to be reliable. Most of DBS and
saliva methods use mainly chromatographic methods that need to
be analytically re-validated (e.g., reference calibration range may
need to be reestablished, etc.) and also clinically validated with
proper reference concentrations to provide the physician an appro-
priate interpretation of the data (Ferrante di Ruffano et al., 2012;
Halling et al., 2012; Kong et al., 2014). Recently, DBS analyses that
do not require complex sample pretreatment have been reported
(Espy et al., 2012). Paper-spray based mass (Wang et al., 2010)
spectrometry demonstrated capability for whole blood analysis
and has been translated in a fully automated sample-to-answer
analyzer that will certainly improve the TAT and the analytical
TDM pipeline (Manicke et al., 2011), although the instrument is
yet too big to fit as a home-based PoC analytical device.
Dried blood spot sample collection is very promising for PoC
devices too, as it could naturally find its way into paper-based lat-
eral flow devices that are definitely much more portable. Lateral
flow devices are recently gaining increasing and renovated inter-
est. Previously, they were confined to clinically important analyses
that require only a yes/no accuracy answer, but no sensitive quan-
tification of the marker. These analyses can be performed with dip
test strips and lateral flow tests, such as tests for infection markers
for human immunodeficiency virus, hepatitis C virus, hepatitis B
(Lee et al., 2010; Gong et al., 2014), tubercolosis (Tsai et al., 2013),
malaria (Horning et al., 2014), tests for the presence/absence of
multi drug resistance Staphylococcus aureus in pre-surgical screen-
ing (Dutta and Dutta, 2006; Yetisen et al., 2013), or the pregnancy
test. The latter is another textbook example of lateral flow tests,
based on colorimetric detection of the analyte on a paper strip
enclosed in a disposable plastic cassette, which provides an internal
control, and a simple yes/no answer (Mark et al., 2010).
Lateral flow test (Mark et al., 2010) and more recently paper-
based micro analytical devices [usually referred to as µPAD
(Lisowski and Zarzycki, 2013; Hu et al., 2014)] are marketed for
application in resource-limited settings for their limited costs,
portability, and easy disposal management (Fiorini and Chiu,
2005); indeed, much effort is spent in overcoming the difficulties
in the development of quantitative lateral flow PoC of comparable
(or improved) sensitivity with standard immunoassays (Ge et al.,
2012). In view of PoC-derived waste management, paper-based
cartridge offer a cheap disposable test strip that is easily disposed of
by incineration with reduced hazardous waste management costs.
Technical and analytical challenges for the development of
reliable, robust, reproducible paper analytical devices have been
extensively reviewed (Sharma et al., 2011; Li et al., 2012; Liana
et al., 2012; Yetisen et al., 2013; Hu et al., 2014). Despite the chal-
lenges, devices able to treat the blood specimen in situ for analysis
have been reported, and can provide the basis for advanced DBS
handling and analysis. As an example, devices able to perform red
blood cell counts and more recently CD4+ cell counts (with blood
matrix treatment in situ) have been marketed to be used as PoC
monitoring in HIV-positive patients (Jokerst et al., 2008).
Recently, use of thread as an alternate cheap affordable and
robust microfluidic substitute has been reported (Li et al., 2010),
although with limited demonstration of quantitative approaches.
Paper devices that do not require microfabrication for the fluidic
part, but based on their fluidic system on cheaper and promising
3D origami techniques have been presented (Ge et al., 2012). At
the moment, quantitative analysis in clinically relevant ranges with
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paper devices has been demonstrated for monitoring of hepatic
enzymes in about 15 min (Pollock et al., 2012), and look a very
promising strategy for other commonly assessed biomarkers. As
colorimetric readout of results is subjective to variability in the
interpretation, use of mobile phones and smartphone is explored
both for off-site consultation and as processor devices. Alternatives
to read-out technologies that do not exploit electronic devices but
are based on counting or signal development time are also under
investigation and validation (Roche et al., 2011; Lewis et al., 2013;
Lutz et al., 2013) to further expand the reach of diagnostics devices
in low-resource settings. Furthermore, much effort is dedicated to
the development of embodied miniaturized battery (also in paper)
for self-sustained devices (Chen et al., 2014b). All these analytical
systems are gaining increasing interest in higher income countries
as well, for their speed, user-friendliness, and predicted impact on
(cheaper) home-based testing.
To fulfill a long-term view of PoC, many researchers explore
alternative matrices to blood in order to avoid even the invasive
fingerpricking. Many studies highlighted a common preference for
saliva over traditional phlebotomy in a majority of cases among
children,parents, and doctors, especially at the onset of the therapy,
when the patient is not yet accustomed to needles (Chee et al., 1993;
Gorodischer et al., 1997; Tennison et al., 2004). In addition, these
less invasive sampling techniques are gaining increasing interests
in pharmacological and epidemiological studies as a simple and
cost-effective alternative to phlebotomy (Parker and Cubitt, 1999;
Ostler et al., 2014). Reproducibility issues of saliva collection in
terms of amount of saliva (in stimulated and unstimulated con-
ditions), sampling timing (Wilson, 2005), interference from food
and residual drug tablets (Schipper et al., 2007), interference in
the MS analysis of the cellulose fibers of some collection devices
have been studied and reported (Shirtcliff et al., 2001). Custom-
made options (Chee et al., 1993) and many commercial kits are
available for sample collection that offer also proprietary buffer for
simple viscosity adjustment (Chiappin et al., 2007; Schipper et al.,
2007). Albeit not all drugs show correlation between serum and
saliva concentrations, saliva is drawing more attention as a suit-
able specimen as it can be seen as naturally ultrafiltrated plasma
(Liu and Delgado, 1999; Za’abi Al et al., 2003; Patsalos and Berry,
2013). Ultrafiltrated plasma sample analyses aim at measuring the
free drug concentration, and not the total plasma concentration;
it is recommended when some pathological or therapeutic condi-
tions are suspected to alter the bound fraction in blood, therefore
modifying the free blood concentration in the patient (Rowland,
1980; Rolan, 1994). Ultrafiltration is a delicate sample pretreat-
ment procedure, and poses analytical challenges to immunoassays,
so that most laboratories prefer standard analytical techniques
(Rukhadze et al., 2000; Tonic-Ribarska et al., 2012; Patsalos and
Berry, 2013). As the amount to be detected is lower in saliva and
ultrafiltrated samples compared to plasma specimens, the assay
has to be analytically validated with appropriate calibration for
lower concentration ranges, which for few drugs happens to be at
the sensitivity limit of the assay (Liu and Delgado, 1999; Za’abi
Al et al., 2003; Patsalos and Berry, 2013). Saliva measurements
are analytically challenging especially for drugs highly bound to
plasma proteins (Liu and Delgado, 1999; Za’abi Al et al., 2003;
Patsalos and Berry, 2013). Let us take the anticonvulsant tiagabine
as an example: total plasma concentration is in the 50–530 nM
range; however, of this total amount, 96% is bound to plasma
protein, and only 4% is free, meaning that the free drug con-
centration is in the 2–21 nM range, requiring carefully validated
HPLC-UV or HPLC-MS protocols. In addition, even though not
commercially available, immunoassay with antibodies in the aver-
age micromolar affinity range would perform poorly at so low con-
centrations (almost three orders of magnitude less of the affinity
constant). Carefully designed immunoassays with fluorescence-
based detection are reported to efficiently detect concentration in
the picomolar range (Liu and Delgado, 1999; Za’abi Al et al., 2003;
Patsalos and Berry, 2013). Here, new technological advances like
nanomaterial-enhanced miniaturized assays could provide sensi-
tivity improvement at reduced costs with little modification at the
implemented TDM pipeline.
PERSPECTIVE ON APPLICATION OF NANOTECHNOLOGY IN
DEVELOPING PoC DEVICES FOR THERAPEUTIC DRUG
MONITORING
Point-of-care devices may be seen as an integrated complex unity
composed of the microfluidic and liquid storage for sample han-
dling and refluxing, a sensor component that detects the molecular
entities through some receptors; a transducer element that convert
the recognition event in a readable signal, for example, an optical
signal or an electric current; a controller and finally the “output
unit” for result communication. In addition, the sampling unit has
to be disposable and contains all the reagents to provide internal
control and calibration for every analysis.
Nanotechnology definitively provides the tools for manip-
ulation and characterization of tiny amount of matter at the
nanoscale. Although many analytes have serum and saliva concen-
trations in the easy reachable micromolar range, the small amount
of sample available for analysis as a PoC (few microliters of blood,
few hundreds of microliters of saliva) calls for techniques able to
detect tiny amount of molecules with little preprocessing of the
sample, in other word, in a very complex and noisy matrix. For this
reason, electrochemical devices with coupled microfluidics able to
attract the analyte and reflux the solution over the sensor have
been mostly applied (Kusnezow et al., 2006), and sensor geom-
etry can be optimized at the nanoscale for improved sensitivity
(Sheehan and Whitman, 2005a; Zheng et al., 2005). Miniaturized
fluidic provide nanoliter drop handling and manipulation that
further improves microfluidics capabilities already available in the
market. Recent advancements in statistical handling of sample
distribution like Digital Microfluidic enable nanodrop handling
and dispensing with quantitative and sensitive detection of few
individual molecules per sample (Nair and Alam, 2008, 2010).
Nanomaterial-enhanced devices may be grouped (for descrip-
tive purposes) into four main categories, depending on the signal
detection technology employed. Mechanical sensors have shown
great potential in detecting very diluted analytes and few patho-
logical or infective cells (Kelley et al., 2014) by measuring a shift
in mechanical properties of the material, like the resonating fre-
quency of the nanostructured sensor. Hybrid nanomechanical and
optoplasmonic sensors were recently used to detect cancer bio-
marker in spiked serum (Bashir, 2004; Arlett et al., 2011) with sub
pictogram per liter sensitivity. Similar resonating nanostructured
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surfaces have been used in controlled environment (i.e., without
complex biological matrix) to exploit super-hydrophobic effect to
concentrate sparse analyte molecules right at the site of detection
(De Angelis et al., 2011; Melli et al., 2011; Dicuangco et al., 2014),
although performance in complex biological matrices have not yet
been demonstrated in the literature and non-specific binding of
abundant serum proteins is a major concern.
Optical read-out technologies span from colorimetric detection
(via cameras or by naked eye) to spectrophotometry, fluorescence,
turbidimetry, or more sophisticated techniques like frustrated
total internal reflection, surface plasmon resonance, and surface
enhanced Raman spectroscopy (Luppa et al., 2011). Most of these
technologies are not yet amenable for extreme miniaturization;
however, examples of small bench-top size instrumentation are
already present. The use of enzymatic conversion of chromogenic
substrate or nanoparticle-aggregation chromatic change has been
used both in homogeneous assay and in lateral flow assay (Luppa
et al., 2011) to signal the qualitative and quantitative presence of
the target analyte. Electronic based transduction has been very
much improved by the use of nanomaterials in sensor surface
development, as the detection of the analyte relies upon the change
in the electronic property of the sensor surface, and transistor
device can be manufactured at low cost. Mainly, these kinds of
devices have been proved effective for the detection of nucleic
acid sequences, for which the intrinsic high affinity and selectivity
of the probing molecules eliminates much of the matrix noises
otherwise associated with protein-based detection.
Electrochemical readouts, however, are the most popular trans-
duction in sensors and sensor development as it is much more
convenient to measure changes in flow currents through a reporter
redox group at the surface sensor. Many nanomaterials, from
nanostructured surface, to polymer, metal NP, and carbon nan-
otubes have shown superior capability as transducer elements. In
addition, these systems can be easily coupled to mass-consumer
electronic and be implemented in already existing PoC analysis
based on the same principle. Carbon nanotubes, for example,
effectively provide enhancement of electrodes transduction capa-
bilities, especially coupled with electrochemical detection of the
analyte (West and Halas, 2003). Different configurations, designed
to be soon compatible with implantable devices, have been pub-
lished able to recognize and quantify anti-inflammatory drug like
naproxene, in spiked serum sample at clinically relevant sensitiv-
ity (Popovtzer et al., 2006; Alonso-Lomillo et al., 2010; Pruneanu
et al., 2011; Cruz et al., 2014; Ihalainen et al., 2014). This design,
for example, is very versatile, as it exploits enzymes involved in
hepatic drug metabolism as receptor elements. Although some of
these enzyme show higher specificity for certain drugs, their selec-
tivity and specificity in real patient sample (which may present
co-medication and interferents) has to be validated.
Nanotechnology offers a plethora of materials that already
proved enhanced quantitative sensitivity (Hockstein et al., 2004;
Wei et al., 2009; Askim et al., 2013), like nanoparticle-based recog-
nition elements or surface-based nanoelectrodes (Alonso-Lomillo
et al., 2009, 2010; Esfandyari-Manesh et al., 2012; Ginja Teixeira
et al., 2013). Electronic-polymer-based sensor and nanostructured
surface sensors reached clinical trials with nano-electronic “noses”
able to “sniff” patterns of volatile organic chemicals that correlates
with lung cancer and gastric pathologies (Sheehan and Whitman,
2005b; Squires et al., 2008) and was evaluated in ongoing clinical
trials. These systems offer high-sensitivity performance on non-
invasive specimen like exhaled breath. In addition, same achieve-
ments have been reported previously on the detection via optical
readout of toxic gases. A sophisticated statistical analysis (like ded-
icated variations of principal components analysis) of a dataset of
pattern recognition results serve as a “calibration curve” for detec-
tion and quantification of the target analyte, that, in this way,
can be identified and quantified through an assembled chemire-
sistor consisting of different, although, cross-reacting elements.
This kind of approach is potential interest also for biomarker and
therapeutic (and abuse) drug monitoring, thus offering some mul-
tiplexing capability and the circumvention of the requirement for
highly non-cross-reactive receptor element.
Similar mathematical approaches have been used to detect
organic pollutants and drugs via chemometric analysis of the flu-
orescence or UV spectroscopy of these compounds in waste water
and even in plasma and urine (Bruls et al., 2009). However, the
need for a spectrophotometer and the limited sensitivity prevents
at the moment a thorough exploitation of this method for effec-
tive TDM purposes. Environmental sciences studying the effect of
drugs and metabolites on waste water treatment and management
pushed the development of novel high-sensitivity portable method
for monitoring waste water. With some design able to accommo-
date biological matrices treatment, these promising technologies
may be translated into TDM devices. Analytical approaches for
environmental studies and quality assessment of the pharma-
ceutical formulation brought the development of very sensitive
electrochemical detection method based on novel nanomaterial-
enhanced electrodes with accurate and reliable analysis of drugs
in formulations, and in a few cases, in spiked biological matrices
(Kelley et al., 2014).
Nanoparticles are employed in a variety of proof-of-principle
sensor devices for their size-depend and interfacial properties,
that offer intrinsic novel characteristics to the sensors compared
to carrier microbeads generally used in current assays. The use
of NP builds not only on their properties, but also on the easy
of surface modifications for capture molecule immobilization,
and for their capability of interrogating the sample themselves
compared to the two-dimensional confinement of receptor in sur-
face sensor that may suffer from mass transport and convective
flux limitations if not carefully designed (Hill and Mirkin, 2006).
Magnetic nanoparticle-based sensors provide enhanced capturing
and separation capabilities and are already implemented in clin-
ical practice for intraoperative monitoring (Justino et al., 2013).
Interesting hybrid [or “multi-scale” (Agasti et al., 2010)] system
have been reported in which both nano and micro materials
are exploited. For example, in the biobarcode assay, magnetic
microparticles functionalized with the capturing antibodies search
for the target analytes, then they are easily concentrated and non-
specific elements of the biological matrix removed through a
magnetic field. The use of DNA-biobarcode NPs as secondary
identification elements allow for sensitive analysis of multiple
analytes in a complex mixture in a microfluidic setting (Sukho-
rukov et al., 2007; Appleyard et al., 2011; Carregal-Romero et al.,
2013).
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Modified metal NP are gaining interest both as active sensing
elements in different applications, such as nucleic acid and pro-
tein detection (Cho et al., 2012), and as a strategy to enhance,
via nanomaterial modification, the analytical performance of sen-
sor devices (He et al., 2005; Patel et al., 2009; Lin et al., 2011;
Tagad et al., 2013). NPs provide with high local density of recep-
tor to enhance analyte binding and detection (de Miguel and
Sanders, 1998; Snowden and Anslyn, 1999; Wiskur and Anslyn,
2001; Wright et al., 2005; Späth and König, 2010) and can enforce
multiplexing capability (Griss et al., 2014). Similar approaches
to capture attomolar concentration of methylmercury with gold
nanoparticle-enhanced electrodes have recently been shown by
Cho et al. (Hong Enriquez et al., 2012) and other groups showed
promising results with other toxic cations in solution (Liu et al.,
2011; Cho et al., 2012), via electronic or electrochemical read-out
technologies.
Most of the concentration ranges of interest for TDM falls in
the micromolar (and sometimes nanomolar range). This means
that in a 10µL whole blood drop (an average fingerprick drop
size), there are about 1012 (1 nM)–1015 (1µM) molecules to be
detected, which is not as challenging as other cases (like detecting
<10 circulating tumor cell in a 1 mL blood sample against roughly
109 of red blood cells and 106 of white blood cells (Touw et al.,
2005; Dasgupta and Wahed, 2014), to give an order of magnitude).
The real advantage of nanomaterials in these applications resides
in extensive miniaturization for extreme portability and tailored
designed of receptive surfaces. Most of the already available assays
rely upon colorimetric/chemiluminescent sensing and are mostly
based on immunoassays or enzymatic assays with substrate speci-
ficity. Many new AEDs are not tested with the immunoassay format
because a suitable specific receptor has not been identified (or
it is not yet available competitively) and its development is too
costly to be appealing for a company without estimation of short-
time payback. In the last 15 years, the field of synthetic receptors
showed huge development in the in silico design of libraries and of
synthetic moieties able to specifically and sensitively capture mol-
ecules of choices for different fields of application (de Miguel and
Sanders, 1998; Snowden and Anslyn, 1999; Wiskur and Anslyn,
2001; Wright et al., 2005; Späth and König, 2010). Successful
examples of tailored synthetic receptor are extremely promis-
ing. A synthetic peptide receptor showed excellent sensitivity in
detecting methotrexate, an anti-cancer drug, in a miniaturized
test that could be re-engineered for other pharmacological mol-
ecules (Griss et al., 2014), and bioinformatics efforts provides
in silico screening of peptide with high affinity for selected target
molecules (Hong Enriquez et al., 2012). These kinds of com-
pounds may be repurposed for a library of specific anti-AED (and
other drug) receptors providing extreme flexibility in the panel
of drug that can be monitored with portable techniques. How-
ever, nanoparticle-based library may offer additional benefit. The
advantage in using monolayer protected gold NPs,coated with self-
assembling bifunctional ligands (Liu et al., 2011; Cho et al., 2012),
as highly sensitive receptors lies in the ease to adapt the system to
different target molecules and therefore to create libraries of recep-
tor NP to be used receptor elements. For example, the design of
a panel of robust inorganic materials with different functionaliza-
tion (such as self-assembled-monolayer-protected metal particles)
as a chemiresistors has provided a very versatile sensor elements
for complex mixture recognition of both toxic gases (Lim et al.,
2009) and exhaled breath (Barash et al., 2009). As the development
of receptor libraries and the production in high yield of those
molecules present a significant hurdle for industrial translation,
there is much interest in developing combinatorial panels like the
aforementioned NP libraries. Because of their robust processabil-
ity, they are readily adapted to automated synthesis and suitable
for high-throughout screening of affinity for target drugs and that
offer easy translation of the same surface design to cheaper core
material.
It is expected that the introduction of a host of structural
and chemical functionalities onto the same nanoscale architecture
will enable more accurate, sensitive, and precise sensor systems
and will provide more robust platforms for quick, reliable, and
portable drug detection as compared to the techniques used now.
The combination of novel statistical analysis (like PCA) already
brought forward how pattern recognition designs may circumvent
the need of highly selective and specific receptor and still pro-
vide high-performance reliable analysis of complex matrices. Even
the development of nanomaterial-based detector system in which
the nanomaterials allow a simple readout in disposable miniatur-
ized systems enable a timely, detailed, and patient-friendly tight
monitoring of therapy that will ultimately benefit the patients
and improve their quality of life by providing a fully optimized
therapeutic regimen.
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